These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room. Gill BC; Ulchaker JC Curr Urol Rep; 2018 Jul; 19(9):72. PubMed ID: 30022307 [TBL] [Abstract][Full Text] [Related]
3. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. Davis NF; Jack GS; Witjes WP; Bjartell A; Caris C; Patel A; de la Taille A; Lawrentschuk N; Bolton DM; Tubaro A World J Urol; 2019 May; 37(5):873-878. PubMed ID: 30145778 [TBL] [Abstract][Full Text] [Related]
4. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
5. Office-Based HE-TUMT Costs Less than Medication over Four Years in Treating Benign Prostatic Hyperplasia. Lerner LB; Thurmond P; Harsch MR; Martinson MS Surg Technol Int; 2015 May; 26():182-9. PubMed ID: 26055008 [TBL] [Abstract][Full Text] [Related]
6. The economics of benign prostatic hyperplasia treatment: a literature review. Kortt MA; Bootman JL Clin Ther; 1996; 18(6):1227-41. PubMed ID: 9001839 [TBL] [Abstract][Full Text] [Related]
7. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. Plosker GL; Goa KL Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827 [TBL] [Abstract][Full Text] [Related]
8. Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. Bellinger AS; Elliott SP; Yang L; Wei JT; Saigal CS; Smith A; Wilt TJ; Strope SA; J Urol; 2012 May; 187(5):1739-46. PubMed ID: 22425128 [TBL] [Abstract][Full Text] [Related]
9. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data. Ahn HS; Kim SJ; Choi JB; Choo SH; Shim KH; Kim SI BJU Int; 2019 May; 123(5A):E79-E85. PubMed ID: 30303597 [TBL] [Abstract][Full Text] [Related]
10. A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. Naslund MJ; Carlson AM; Williams MJ J Urol; 2005 Jun; 173(6):2090-3; discussion 2093. PubMed ID: 15879849 [TBL] [Abstract][Full Text] [Related]
11. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137 [TBL] [Abstract][Full Text] [Related]
12. Economics of different treatment options of benign prostatic hyperplasia in Turkey. Ilker Y; Tarcan T; Akdaş A Int Urol Nephrol; 1996; 28(4):525-8. PubMed ID: 9119638 [TBL] [Abstract][Full Text] [Related]
13. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. Speakman M; Kirby R; Doyle S; Ioannou C BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness in the management of benign prostatic hyperplasia: Italian data. Di Silverio F; D'Eramo G; Flammia GP; Sciarra A; Buscarini M; Mauro M; Sciarra F Minerva Urol Nefrol; 1994 Jun; 46(2):93-9. PubMed ID: 7526475 [TBL] [Abstract][Full Text] [Related]
15. Comparing Outcomes of Medical Management and Minimally Invasive Surgical Techniques for Lower Urinary Tract Symptoms due to BPH. Sterling J; Farber N; Gupta NK Curr Urol Rep; 2019 Apr; 20(6):29. PubMed ID: 30989392 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Ackerman SJ; Rein AL; Blute M; Beusterien K; Sullivan EM; Tanio CP; Manyak MJ; Strauss MJ Urology; 2000 Dec; 56(6):972-80. PubMed ID: 11113743 [TBL] [Abstract][Full Text] [Related]